Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q1 FY23 results · Apr–Jun 2022
Marksans Pharma reported revenue from operations of ₹433.77 crore (up 24.3% from Q1 FY22) and net profit of ₹60.18 crore (down 3.9% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 433.77 | 348.96 | +24.3% | 418.04 | +3.8% |
| Other income | 16.50 | 5.88 | +180.4% | 15.34 | +7.5% |
| Total income | 450.27 | 354.85 | +26.9% | 433.39 | +3.9% |
| Profit before tax | 76.44 | 74.78 | +2.2% | 52.60 | +45.3% |
| Net profit for the period | 60.18 | 62.60 | −3.9% | 29.65 | +103.0% |
| Attributable to shareholders of the company | 59.72 | — | — | — | — |
| EPS, basic (₹) | 1.46 | 1.51 | −3.3% | 0.69 | +111.6% |
| Net margin (%) | 13.9 | 17.9 | 7.1 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 159.15 | 147.22 | +8.1% | 176.28 | −9.7% |
| Other income | 19.43 | 13.94 | +39.4% | 7.65 | +154.1% |
| Total income | 178.58 | 161.16 | +10.8% | 183.93 | −2.9% |
| Profit before tax | 25.70 | 34.18 | −24.8% | 28.63 | −10.2% |
| Net profit for the period | 19.21 | 28.91 | −33.6% | 21.43 | −10.4% |
| EPS, basic (₹) | 0.47 | 0.71 | −33.8% | 0.52 | −9.6% |
| Net margin (%) | 12.1 | 19.6 | 12.2 |
Consolidated
- Filed with BSE
- 16 Aug 2022, 09:07 IST
- Board meeting
- 13 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 16 Aug 2022, 09:07 IST
- Board meeting
- 13 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE